Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: COVID 19 post moderna covid-19 vaccination/experiencing COVID rebound after completing Paxlovid, then tested negative and tested positive again. still testing positive; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID 19 post moderna covid-19 vaccination/experiencing COVID rebound after completing Paxlovid, then tested negative and tested positive again. still testing positive) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Anxiety, Inflammatory bowel disease, GERD and Drug allergy (Erythromycin).    On 03-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID 19 post moderna covid-19 vaccination/experiencing COVID rebound after completing Paxlovid, then tested negative and tested positive again. still testing positive). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 24-May-2022 to 28-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID 19 post moderna covid-19 vaccination/experiencing COVID rebound after completing Paxlovid, then tested negative and tested positive again. still testing positive) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-May-2022, SARS-CoV-2 test: positive (Positive) experiencing COVID  rebound After completing Paxlovid. On 30-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 31-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 02-Jun-2022, SARS-CoV-2 test: positive (Positive) tested positive again. In June 2022, SARS-CoV-2 test: positive (Positive) still testing positive.         No Concomitant medication was reported  Patient appeared to be experiencing COVID rebound after completing Paxlovid on 28-May-2022..On 02-Jun-2022 patient began to have nasal congestion. Patient still experiencing nasal congestion as of 03-Jun-2022   Device Date was reported as 03-Jun-2022 company comment This is a spontaneous case concerning a 42-year-old female patient with no relevant medical history reported, who experienced the non-serious, unexpected AESI event of COVID-19, which occurred on an unknown date after receiving the 3rd dose of mRNA-1273 vaccine in the covid 19 vaccination series. Details of primary doses were not provided. It was reported that the patient received treatment with Paxlovid for 5 days from 24 May to 28 May 2022, for covid 19. It was reported that the covid test was positive on the day paxlovid was stopped, then became negative 2 days later and she was experiencing COVID rebound with a positive test again on 02 June, 5 days after stopping paxlovid and it remained positive. 02-Jun-2022 patient began to have nasal congestion. Patient was still experiencing nasal congestion as of 03-Jun-2022 and this event had not resolved. The ongoing Covid 19 pandemia is a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event seriousness assessed per medical judgement.; Sender's Comments: This is a spontaneous case concerning a 42-year-old female patient with no relevant medical history reported, who experienced the non-serious, unexpected AESI event of COVID-19, which occurred on an unknown date after receiving the 3rd dose of mRNA-1273 vaccine in the covid 19 vaccination series. Details of primary doses were not provided. It was reported that the patient received treatment with Paxlovid for 5 days from 24 May to 28 May 2022, for covid 19. It was reported that the covid test was positive on the day paxlovid was stopped, then became negative 2 days later and she was experiencing COVID rebound with a positive test again on 02 June, 5 days after stopping paxlovid and it remained positive. 02-Jun-2022 patient began to have nasal congestion. Patient was still experiencing nasal congestion as of 03-Jun-2022 and this event had not resolved. The ongoing Covid 19 pandemia is a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event seriousness assessed per medical judgement.